Phase I study of bortezomib and 153Sm-lexidronam combination for refractory and relapsed multiple myeloma.

被引：0
|
作者：
Yeh, H. S.
Swift, R. A.
Ferretti, D.
Mapes, R. A.
Goeckeler, W. F.
Berenson, J. R.
机构：
[1] Inst Myeloma & Bone Canc Res, W Hollywood, CA USA
[2] Oncotheraoeut Inc, W Hollywood, CA USA
[3] Cytogen Corp, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：450S / 450S
页数：1
相关论文
共 50 条
  • [1] Phase I study of bortezomib and 153Sm-Lexidronam combination for refractory and relapsed multiple myeloma.
    Berenson, James R.
    Swift, Regina A.
    Mapes, Russell
    Abaya, Christina D.
    BLOOD, 2006, 108 (11) : 1011A - 1012A
  • [2] Phase I trial of bortezomib and Samarium Sm 153 lexidronam in refractory and relapsed multiple myeloma
    Berenson, James R.
    Patel, Ravi
    Yellin, Ori
    Swift, Regina A.
    CANCER INVESTIGATION, 2007, 25 : 33 - 33
  • [3] A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
    Berenson, James R.
    Yellin, Ori
    Patel, Ravi
    Duvivier, Herb
    Nassir, Youram
    Mapes, Russell
    Abaya, Christina DiLauro
    Swift, Regina A.
    CLINICAL CANCER RESEARCH, 2009, 15 (03) : 1069 - 1075
  • [4] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Ocio, Enrique M.
    Mateos, Maria-Victoria
    Prosper, Felipe
    Martin, Jesus
    Rocafiguera, Albert Oriol
    Jarque, Isidro
    Iglesias, Rebeca
    Motlloo, Cristina
    Sole, Maria
    Rodriguez-Otero, Paula
    Martinez, Sara
    Fernandez-Garcia, Eva
    Michot, Jean-Marie
    Soto-Matos, Arturo
    Diaz-Pavon, Jose Rodriguez
    Ribrag, Vincent
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Phase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myeloma.
    Chari, A
    Kaplan, L
    Linker, C
    Damon, LE
    Navarro, WH
    Martin, T
    BLOOD, 2005, 106 (11) : 379B - 379B
  • [6] A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma.
    Lonial, Sagar
    Francis, Dixil
    Karanes, Chatchada
    Trudel, Suzanne
    Dollard, Akari M.
    Aceo, Fermin
    Gul, Engin
    Kakar, Sumeet
    Krishnan, Amrita Y.
    Reece, Donna E.
    Harvey, R. Donald
    Kaufman, Jonathan L.
    BLOOD, 2009, 114 (22) : 1481 - 1481
  • [7] Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
    Badros, Ashraf
    Burger, Angelika M.
    Philip, Sunita
    Niesvizky, Ruben
    Kolla, Sarah S.
    Goloubeva, Olga
    Harris, Carolynn
    Zwiebel, James
    Wright, John J.
    Espinoza-Delgado, Igor
    Baer, Maria R.
    Holleran, Julianne L.
    Egorin, Merrill J.
    Grant, Steven
    CLINICAL CANCER RESEARCH, 2009, 15 (16) : 5250 - 5257
  • [8] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Phase lb study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.
    Laubach, Jacob
    Tuchman, Sascha Alexander
    Rosenblatt, Jacalyn
    Redd, Robert
    Colson, Kathleen
    Motta, Ashley
    Fitzpatrick, Kathleen
    Weller, Edie
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Phase I/II study of Sm-153 lexidronam, limb irradiation and stem cell transplantation for the treatment of multiple myeloma.
    Durrant, S
    Irving, I
    Mollee, P
    Morton, AJ
    Webb, M
    Macfarlane, D
    BONE MARROW TRANSPLANTATION, 2001, 27 : S41 - S41
12345